Quest Diagnostics today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.
The laboratory-developed test, named AD-Detect Abeta 42/40 and p-tau217 Evaluation, combines results of blood levels of amyloid beta (AB) 42/40 determined by the company's proprietary tandem mass spectrometry techniques with blood levels of p-tau217 determined by an in vitro immunoassay test. The test results are then used to produce the AD-Detect Likelihood Score, a composite interpretation created through a proprietary algorithm validated utilizing a well-characterized cohort from the 1Florida Alzheimer's Disease Research Center (ADRC).
The new Quest test panel builds on prior AD-Detect tests that individually assess AB 42/40 and p-tau217, as well as p-tau181 and the ApoE isoform, a genetic risk marker. Those tests help providers assess risk of AD rather than confirm likelihood of amyloid brain pathology due to AD.
